A parent’s guide to understanding meningococcal B disease

Multicomponent Meningococcal group B vaccine(recombinant, adsorbed)

1.van Deuren M, et al. Clin Microbiol Rev. 2000;13(1):144–166. 2.Thompson MJ, et al. Lancet 2006; 367(9508): 397–403. 3.GlaxoSmithKline NZ. Bexsero Data Sheet 2018. Available at: http://www.medsafe.govt.nz/profs/Datasheet/b/bexseroinj.pdf Accessed: 15 August 2018. 4.Immunisation Advisory Centre. Bexsero: A vaccine to protect against meningococcal group B disease Fact Sheet. Available at http://www.immune.org.nz/sites/default/files/resources/Written%20Resources/NonprogrammeVaccine BexseroImac20180912V01Final.pdf . Accessed 15 September 2018. 5.Rosenstein NE, et al. N Engl J Med 2001; 344(18): 1378–88. 6.The Institute of Environmental Science and Research. Notifiable Diseases in New Zealand Annual Report 2016. Available at: https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2016/2016AnnualNDReportFinal.pdf Accessed: 3rd July 2018. 7.Christiensen H, et al. Lancet Infect Dis 2010;10:853–61. 8.Ministry of Health, Wellington. Meningococcal disease (including meningitis). Summary Tab. Available at: https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/meningococcal-disease-including-meningitis Accessed 12 July 2018. 9.The Institute of Environmental Science and Research. The Epidemiology of Meningococcal Disease in NZ 2008-2013 Surveillance Reports. Available at: https://surv.esr.cri.nz/surveillance/Meningococcal_disease.php Accessed:3rd July 2018. 10.The Institute of Environmental Science and Research. Notifiable Diseases in New Zealand Annual Surveillance Reports 2014-2016. Available at: https://surv.esr.cri.nz/surveillance/annual_surveillance.php Accessed: 3rd July 2018. 11.The Institute of Environmental Science and Research, Meningococcal disease epidemiology data request. GSK. 2017. 12.Immunisation Advisory Centre. NZ National Immunisation Schedule. Available at: http://www.immune.org.nz/new-zealand-national-immunisation-schedule Accessed: 3rd July 2018. 13.Ministry of Health. Immunisation Handbook 2017 (2nd Edition, March 2018). Available at https://www.health.govt.nz/publication/immunisation-handbook-2017. Accessed 14 August 2018. 14.Centres for Disease Control and Prevention website. Meningococcal disease. Available at: https://www.cdc.gov/meningococcal/about/prevention.html. Accessed 11 July 2018. 15.Ministry of Health. Meningococcal Disease – Don’t Wait Take Action. Available at: https://www.healthed.govt.nz/resource/meningococcal-disease-dont-wait-take-action Accessed 15 August 2018 Bexsero® (Multicomponent Meningococcal group B Vaccine) is available as an injection. Bexsero is for immunisation against invasive disease caused by N. meningitidis group B from 2 months of age or as per official recommendations. Bexsero is available as a private-purchase prescription medicine – you will have to pay normal doctor’s visit fees and a prescription charge. A trained pharmacist can also administer Bexsero to a person aged 16 years and older. A 0.5 mL dose contains contains 50mcg of Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein, 50mcg of Neisseria meningitidis Group B Neisseria Adhesin A protein, 50mcg of Neisseria meningitidis Group B Factor H Binding Protein fusion protein, 25 mcg of Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4. Bexsero has risks and benefits. Bexsero should not be administered if you or your child are hypersensitive to any component of this vaccine Common side effects Infants & Toddlers: eating disorders, sleepiness, unusual crying, diarrhoea, vomiting, rash, fever (≥39.5°C), injection site reactions, irritability, arthralgia. Adolescents & Adults: headache, nausea, injection site reactions, malaise, myalagia, arthralgia. If you or your child have side effects, see your doctor, pharmacist, or health professional. Additional Consumer Medicine Information for Bexsero is available at www.medsafe.govt.nz. Ask your doctor if Bexsero is right for you or your child. Bexsero is a registered trade mark of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. TAPS NA10450/18SE/VAC/0018/18. GSK00691Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.

Multicomponent Meningococcal group B vaccine(recombinant, adsorbed)

Early symptoms of meningococcal disease may appear mild – similar to those of a cold or the flu. However, symptoms can progress quickly and may include:15

KNOW THE SIGNS & SYMPTOMS

High fever

Sometimes, red or purple spots or

bruises on the skin

Vomiting

Dislike bright lightsStiff neck

10:00 AM 10:00 PMAdditional symptoms in babies may include: Cold hands and feet or shivering, being floppy or harder to wake, unusual crying and refusal to eat.

Additional symptoms in older children and adults may include:

Headache, confusion, joint pain and aching muscles.

Don’t wait for spots to appear before getting medical help. Seek medical

attention immediately if you see one or more of the symptoms above15

Sleepiness

Meningococcal B (commonly known as meningitis) can change life in a moment1,2

Thankfully, Bexsero is available to help protect against it.3

FOR MORE INFORMATION

0800 466 863www.immune.org.nz www.meningitis.org.nz

MENINGITISB.CO.NZ

0800 611 11624 hours a day

GROUP B

70%

WHAT IS MENINGOCOCCAL DISEASE?

GROUP W

7.5%

GROUP Y

10.5%

GROUP C

12%

70% OF MENINGOCOCCAL CASES IN NEW ZEALAND ARE CAUSED BY GROUP B*6 There are several different groups of meningococcal bacteria, of which there are five groups that most commonly cause disease (A, B, C, W and Y).8 In 2016, reported cases of meningococcal disease in New Zealand were caused by:6*

And up to 1 in 5 can suffer from serious long-term disabilities,

including brain damage, deafness, and limb loss.4,5

* of those cases that could be typed, 2016 ESR data.

HOW IS IT SPREAD?The bacteria that cause meningococcal disease live within the nose and throat. Around 10 - 20% of people will carry the bacteria at any one time, without ever becoming ill.7

They can be spread through everyday behaviours, including:8

WHO’S AT RISK? Anyone can get meningococcal B, however babies and children under 5 are at most risk, followed by teens.9,10

BEXSERO IS A VACCINE THAT CAN HELP PROTECT AGAINST MENINGOCOCCAL B3

Bexsero is given by injection and the number of doses needed depends on the age of the person being vaccinated.3

Bexsero is not currently included on the New Zealand National Immunisation Schedule so you will need to pay for Bexsero.12

As with other vaccines, Bexsero has benefits and risks.3

IS YOUR CHILD OR TEEN PROTECTED AGAINST MENINGOCOCCAL B? Probably not. The New Zealand National Immunisation Schedule does not currently include a vaccine to protect against meningococcal B.12

Some people would have received the MeNZB™ vaccine between 2004 and 2008. MeNZB was temporarily introduced in New Zealand to control an epidemic of meningococcal B. The protection from this vaccine was not long-lasting, so these people are unlikely to still be protected against meningococcal B.13

Coughing & sneezing Sharing drinks & eating utensils

KissingLiving in close quarters

Babies

Meningococcal disease is an uncommon but serious infection caused by the bacteria Neisseria meningitidis. A person with meningococcal disease can develop meningitis (inflammation of the membrane around the brain), septicaemia (blood infection) or pneumonia. It strikes and progresses quickly - usually without warning.2,4

ABOUT 1 IN 10 INFECTED WITH MENINGOCOCCAL DISEASE CAN DIE, SOMETIMES WITHIN 24 HOURS 2,4,5

Under 5s Teens

In New Zealand, over half of meningococcal B cases occur in children

under 5 years of age.11

MOST NEW ZEALANDERS ARE NOT CURRENTLY PROTECTED AGAINST

MENINGOCOCCAL B

Ask your healthcare professional about vaccination with Bexsero to help protect

against meningococcal B.3